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Abstract 
Niemann-Pick C1-Like 1 (NPC1L1) mediates intestinal absorption of dietary and biliary 
cholesterol. Ezetimibe, by inhibiting NPC1L1 function, is widely used to treat 
hypercholesterolemia in humans. Interestingly, ezetimibe treatment appears to attenuate hepatic 
steatosis in rodents and humans without a defined mechanism. Overconsumption of a high-fat 
diet (HFD) represents a major cause of metabolic disorders including fatty liver. To determine 
whether and how NPC1L1 deficiency prevents HFD-induced hepatic steatosis, in this study, we 
fed NPC1L1 knockout (L1-KO) mice and their wild-type (WT) controls an HFD, and found that 
24 weeks of HFD feeding causes no fatty liver in L1-KO mice. Hepatic fatty acid synthesis and 
levels of mRNAs for lipogenic genes are substantially reduced but hepatic lipoprotein-
triglyceride production, fatty acid oxidation, and triglyceride hydrolysis remain unaltered in L1-
KO versus WT mice. Strikingly, L1-KO mice are completely protected against HFD-induced 
hyperinsulinemia under both fed and fasted states and during glucose challenge. Despite similar 
glucose tolerance, L1-KO relative WT mice are more insulin sensitive and in the overnight-
fasted state display significantly lower plasma glucose concentrations. In conclusion, NPC1L1 
deficiency in mice prevents HFD-induced fatty liver by reducing hepatic lipogenesis, at least in 
part, through attenuating HFD-induced insulin resistance, a state known to drive hepatic 
lipogenesis through elevated circulating insulin levels. 
Keywords: ezetimibe, nonalcoholic fatty liver disease, intestinal cholesterol absorption, insulin 
resistance, obesity 
Niemann-Pick C1-Like 1 (NPC1L1) is a polytopic transmembrane protein essential for intestinal 
absorption of both biliary and dietary cholesterol (1, 2). The tissue distribution of NPC1L1 
expression differs among species. In humans, NPC1L1 is abundantly expressed in both small 
intestine and liver (2–4). In rodents, NPC1L1 is almost exclusively expressed in the small 
intestine where it resides at the apical membrane of absorptive enterocytes (2). NPC1L1 
knockout (L1-KO) mice are resistant to high-cholesterol diet-induced hypercholesterolemia due 
to a substantial reduction in intestinal cholesterol absorption (2, 5, 6). 
NPC1L1 is the target of ezetimibe (7, 8), a potent cholesterol absorption inhibitor that is widely 
used to lower blood low density lipoprotein (LDL)-cholesterol in humans (9). Unexpectedly, 
ezetimibe treatment or NPC1L1 deficiency was recently shown to improve many metabolic 
disorders besides hypercholesterolemia in rodents and in obese humans (10, 11). For instance, 
ezetimibe treatment lessened hepatic steatosis and improved insulin sensitivity in leptin receptor-
deficient Zucker obese rats (12, 13). Ezetimibe also reduced hepatic steatosis in mice on the 
methionine choline-deficient diet (14) or diets containing high amounts of cholesterol (15). In a 
study focusing on obesity and diabetes, ezetimibe treatment or NPC1L1 deficiency was shown to 
attenuate weight gain and insulin resistance in mice on a high-fat diet (HFD), though it remains 
to be determined whether this intervention influences the development of hepatic steatosis (16). 
In another study focusing on the role of NPC1L1 in protein trafficking and diet-induced 
hypercholesterolemia, L1-KO mice were observed to be resistant to hepatic steatosis induced by 
the Paigen diet, a lithogenic diet that contains high amounts of bile acid and cholesterol (3). 
Additionally, ezetimibe treatment significantly decreased hepatic triglyceride content in obese 
humans on a weight loss diet (10). Despite these interesting observations, mechanisms by which 
NPC1L1 deficiency or ezetimibe treatment alleviates hepatic steatosis, insulin resistance, and 
obesity remain largely unexplored. 
Hepatic steatosis, steatohepatitis, fibrosis, and cirrhosis are collectively known as nonalcoholic 
fatty liver disease (NAFLD) (17). In the general population, the estimated prevalence of NAFLD 
could be as high as 24% (18). Hepatic steatosis may occur in 17–33% of Americans (19), 
representing a burgeoning health problem worldwide. Fat overconsumption plays an important 
role in the etiology of hepatic steatosis. Effects of NPC1L1 deficiency on HFD-induced hepatic 
steatosis have not been examined. Earlier studies were performed with animals that were either 
deficient in leptin pathway (12, 13) or challenged with a nonphysiological diet (3, 14) or a diet 
containing high amounts of cholesterol (15). 
Different diets cause hepatic steatosis likely through distinct mechanisms. For animals on a high-
cholesterol diet, it is conceivable that NPC1L1 deficiency or ezetimibe treatment may reduce 
hepatic steatosis by attenuating cholesterol-dependent liver X receptor (LXR) activation (20) and 
LXR activation-induced lipogenesis (21) through limiting intestinal cholesterol absorption. 
Consistent with this, we found that L1-KO relative to wild-type (WT) mice accumulate less 
triglyceride in liver after treatment with T0901317 (22), a synthetic LXR agonist that promotes 
hepatic lipogenesis (21). During HFD feeding, animals develop insulin resistance, a pathological 
state that is associated with elevated circulating insulin levels. In this state, the liver is selectively 
resistant to insulin-induced suppression of gluconeogenesis, but stays sensitive to insulin-
stimulated activation of sterol regulatory element-binding protein (SREBP)-1c (23), a 
membrane-bound transcription factor whose activation promotes lipogenesis (24), thereby 
developing steatosis (25). Hepatic steatosis itself may in turn dampen insulin signaling and 
therefore aggravate hepatic and systemic insulin resistance (26). This vicious cycle represents an 
important mechanism underlying HFD-induced insulin resistance and hepatic steatosis. We 
hypothesized that NPC1L1 deficiency may prevent HFD-induced hepatic steatosis mainly by 
stopping this vicious cycle. Consistent with this hypothesis, in this study, we showed that 24 
weeks of HFD feeding does not cause hepatic steatosis in L1-KO mice and the plasma insulin 
level is reduced by ∼85% in these animals relative to WT mice, which is associated with 
substantially reduced hepatic fatty acid synthesis and levels of mRNAs for all the lipogenic 
genes examined. Thus, the HFD-driven insulin resistance-hepatic steatosis vicious cycle was 
completely blocked in NPC1L1-deficient mice. Our findings may promote clinical studies of 
ezetimibe effects on hepatic steatosis and the associated metabolic disorders in humans. 
MATERIALS AND METHODS 
Animals and diets 
L1-KO mice of pure C57BL/6 background were reported previously (3). All mice were housed 
in a specific pathogen-free animal facility in plastic cages at 22°C with a daylight cycle from 
6AM to 6PM. The mice were provided with water and standard chow diet (Prolab RMH 3000) 
ad libitum unless stated otherwise. All animal procedures were approved by the Institutional 
Animal Care and Use Committee at Wake Forest University Health Sciences. Male L1-KO mice 
and their WT controls were fed an HFD (TD.93075; Harlan Teklad, Madison, WI) for 24 weeks 
starting at 6 weeks of age. The HFD derives 54.8% calories from fat, 21.2% calories from 
protein, and 24% calories from carbohydrates. It contains only a trace amount of cholesterol 
(∼0.007%). The fatty acid composition in the fat of this diet is 28% saturated-, 30% 
monounsaturated-(trans), 28% monounsaturated-(cis), and 14% polyunsaturated-(cis) fatty acids 
(27). 
Fecal neutral sterol excretion and intestinal cholesterol absorption 
After 18 weeks on an HFD, mice were used for the determination of fecal neutral sterol excretion 
and intestinal cholesterol absorption as we have described previously (28). 
Intestinal fat absorption 
After 13 weeks on an HFD, mice were individually housed and fed for 7 days a test diet with a 
composition similar to the HFD except 5% of fat in the test diet was replaced by the 
nonabsorbable marker, sucrose poly-behenate (29). The test diet was prepared by our diet core in 
the primate center of Wake Forest University Health Sciences. In the last 3 days of test diet 
feeding, fecal samples were collected. The fatty acid content and composition in both the diet 
and feces were determined by gas chromatography and the fractional absorption of total and 
individual fatty acids was calculated as described previously (29). 
Blood biochemistries 
Plasma insulin and adiponectin were measured by Ultra Sensitive Mouse Insulin ELISA Kit 
(Crystal Chem, Inc.) and Quantikine Mouse Adiponectin/Acrp30 (R & D Systems), respectively. 
Fed and fasted plasma glucose levels were measured by Glucose Assay Kit (Cayman Chemical 
Co.). Plasma β-hydroxybutyrate (LiquiColor, Stanbio) and nonesterified fatty acids [HR Series 
NEFA-HR (2), Wako] were measured following the manufacturer's instructions. Plasma 
concentrations of total cholesterol, free cholesterol, and triglyceride were analyzed using the 
Cholesterol/HP (Roche), the Free Cholesterol C (Wako), and Triglycerides/GB (Roche) 
enzymatic assay kits, respectively. 
Liver lipids 
After a 4 h fast during the daylight cycle, mice were euthanized after bleeding and livers 
removed and snap-frozen in liquid nitrogen for liver lipid analysis as we have described 
previously (4). 
Liver histopathology 
Livers were fixed in 10% buffered formalin and processed for hematoxylin and eosin (H and E) 
staining in the clinical laboratory of our department. 
De novo cholesterol and fatty acid synthesis in liver 
These measurements were performed as described previously by Mulvihill, et al. (30). After 6 
weeks of HFD feeding, mice were fasted for 4 h followed by intraperitoneal injection of 10 µCi 
of [1-14C]acetic acid (PerkinElmer, Boston, MA). One hour later, mice were euthanized. Liver 
tissues (∼250 mg) were collected, saponified in 2.2 ml of a mixture of 50% potassium hydroxide 
in water and 95% ethanol (1:10), and then extracted by 3 ml of hexane. The sterol-containing 
hexane extract was dried down by nitrogen gas and then solubilized in scintillation cocktail for 
scintillation counting for the determination of de novo hepatic cholesterol synthesis. The 
remaining aqueous phase was acidified with 0.8 ml of glacial acetic acid (pH 6), extracted by 3 
ml of hexane, and processed for scintillation counting for the determination of de novo hepatic 
fatty acid synthesis. 
Hepatic fatty acid oxidation 
Fatty acid oxidation activity was measured as previously described (31). After 6 weeks of HFD 
feeding, mice were fasted for 4 h. Fresh liver tissue (∼200 mg) was homogenized in four 
volumes of 0.25 M sucrose containing 1 mM EDTA. About 5 mg of tissue homogenate was 
incubated for 30 min at 25°C in a buffer containing 150 mM KCl, 10 mM HEPES (pH 7.2), 0.1 
mM EDTA, 1 mM potassium phosphate buffer (pH 7.2), 5 mM malonate, 10 mM MgCl2, 1 mM 
carnitine, 0.15% fatty acid free-BSA, 5 mM ATP, and 50 μM palmitic acid containing 1 μCi of 
[9,10(n)-3H] palmitic acid (PerkinElmer). Reactions were stopped with the addition of 200 μl 0.6 
N perchloric acid. Unreacted fatty acids were removed by hexane extraction. Radioactive 
degradation products in the aqueous phase were counted and the data were presented as 
DPM/min/mg liver protein. 
Liver triglyceride production 
Hepatic triglyceride production was measured as described previously (32). After a 4 h fast, mice 
were anesthetized and injected with Tyloxapol (Triton WR-1339) (Sigma) at 500 mg/kg body 
weight (BW) via the retro-orbital vein to block lipolysis. Each mouse received ∼100 μl of saline 
solution containing 15 g/dl Tyloxapol. Blood samples were collected at 0, 30, 60, 90, 120, and 
180 min after injection. Plasma triglyceride concentrations were measured by the enzymatic 
assay described above. Linear regression line was drawn against plasma triglyceride 
concentrations of individual animals versus their corresponding time points using GraphPad 
Prism 5. The triglyceride secretion rate was derived from the slope of the line. 
Liver triglyceride hydrolase activity 
Liver triglyceride hydrolase activity was measured in the cytosolic extracts of livers from L1-KO 
and WT mice fed an HFD for 24 weeks as described previously using lipid droplets isolated from 
HepG2 cells as substrates (33, 34). For radioactive labeling of lipid droplets, HepG2 cells were 
treated with 2.5 µCi [3H-9,10]oleic acid/ml + 0.8 mM cold oleic acid complexed to BSA for 16 
h. Cells were then washed with ice-cold PBS and centrifuged (1000 g at 4°C for 10 min). The 
supernatant was removed and the cells were resuspended in ice-cold hypotonic lysis medium 
(HLM) (20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10 mM sodium fluoride, and protease inhibitor 
cocktail). To isolate lipid droplets, resuspended cells were transferred to a Potter-Elvehjem tissue 
homogenizer and gently homogenized on ice. After centrifugation, the supernatant and floating 
fat layer were collected and adjusted to a final concentration of 20% sucrose in HLM. This was 
layered into a 13.2 ml ultracentrifuge tube and gently overlaid with 5 ml ice-cold HLM 
containing 5% sucrose. The remainder of the tube was filled with HLM and centrifuged at 
28,000 g at 4°C for 30 min using an SW40 rotor. The floating white lipid droplet layer was 
collected and triglyceride (TG) contents were determined enzymatically. For the determination 
of hepatic triglyceride hydrolase activity, the cytosolic extracts were prepared by homogenizing 
liver samples in buffer A (0.25 M sucrose, 1 mM EDTA, 1 mM DTT, and protease inhibitor 
cocktail). Homogenate was centrifuged at 20,000 g for 30 min at 4°C. The infranatant was 
removed and ultracentrifuged at 100,000 g for 1 h at 4°C. One hundred micrograms of the 
triglyceride-free infranatant was incubated with 25 nmol [3H-9,10]oleate labeled lipid droplet 
substrate and 5% BSA in a total volume of 200 μl for 1 h at 37°C. The reaction was stopped by 
adding 3.25 ml of methanol:chloroform:heptane (10:9:7) and 1 ml of 0.1 M potassium carbonate, 
and 0.1 M boric acid (pH 10.5). After centrifugation, the radioactivity in 1 ml of the upper phase 
was determined by scintillation counting. 
Glucose and insulin tolerance tests 
For glucose tolerance tests, mice were fasted for 10 h. After measuring the baseline blood 
glucose level via a tail nick using a Glucometer (Bayer Contour), a 20% glucose solution was 
injected intraperitoneally at 1.5 mg/g BW. Blood glucose levels were then measured at 15, 30, 
60, and 120 min after glucose injection. For insulin tolerance tests, mice were fasted for 6 h. 
After measuring the baseline blood glucose level, mice were injected intraperitoneally with 
recombinant human insulin (Novo Nordisk, Inc.) at 1.2 mU/g BW, and their blood glucose 
concentrations were determined at 15, 30, 60, and 120 min post insulin administration. 
Glucose-stimulated insulin secretion 
Glucose-stimulated insulin secretion was performed as described (35). Seven-week-old chow fed 
WT mice or 6-week-old WT and L1-KO mice on an HFD for 5 weeks were fasted for 10 h and a 
bolus of 20% glucose was injected into the intraperitoneal cavity at 1.5 mg/g BW. Blood samples 
were collected at 0, 15, and 30 min from tails for plasma insulin determination using an ELISA 
kit (Crystal Chem, Inc.). 
qPCR 
The quantitative real-time PCR (qPCR) was performed as described previously (36). All primers 
used for qPCR are available upon request. 
Hepatic oxidative stress 
Hepatic levels of the lipid peroxidation product malondialdehyde were measured as 
thiobarbituric acid reactive substrates (TBARS) using the TBARS Assay Kit (Cayman Chemical 
Co.). Hepatic redox environment was determined by measuring glutathione (GSH)/oxidized 
glutathione (GSSG) ratio using Glutathione Assay Kit (Cayman Chemical Co.). 
Statistical analysis 
Data are expressed as mean ± SEM. The difference between the mean values of L1-KO and WT 
groups was tested for statistical significance by two-tailed Student's t-tests. A value of P < 0.05 
was accepted as statistically significant. 
RESULTS 
NPC1L1 deficiency promotes loss of endogenous cholesterol in mice on an HFD 
Currently, there are no studies of the effects of NPC1L1 deficiency on cholesterol metabolism in 
mice on an HFD containing no added cholesterol. To fill this gap in knowledge, we examined 
cholesterol balance in L1-KO mice on an HFD. Consistent with a critical role of NPC1L1 in 
intestinal cholesterol absorption, L1-KO versus WT mice displayed a 97% reduction in intestinal 
cholesterol absorption (Fig. 1A) and a 91% increase in fecal excretion rate of neutral sterols 
(cholesterol and its bacterial metabolites) (Fig. 1B). Because our HFD contains almost no 
cholesterol, these increased fecal neutral sterols must come from biliary and perhaps intestinal 
(37, 38) secretion of endogenously synthesized cholesterol. To compensate for excessive loss of 
cholesterol from the body, hepatic endogenous cholesterol synthesis was increased by ∼7-fold 
(Fig. 1C) and transcripts of cholesterol biosynthetic enzymes, such as 3-hydroxy-3-methyl-
glutaryl CoA (HMG-CoA) reductase, HMG-CoA synthase, and squalene synthase, were all 
upregulated in L1-KO livers (supplementary Table I). Despite this compensatory mechanism, 
plasma levels of total cholesterol, free cholesterol, cholesteryl ester, and hepatic contents of total 
cholesterol and cholesteryl ester were significantly reduced in L1-KO relative to WT mice on an 
HFD for 24 weeks (Fig. 1D, E), and their levels were similar to those observed in chow-fed 
animals. 
NPC1L1 deficiency prevents HFD-induced hepatic steatosis 
To determine if genetic ablation of NPC1L1 influences HFD-induced hepatic steatosis, we 
examined livers from mice on an HFD for 24 weeks. As expected, livers from WT mice were 
enlarged (Table 1) and appeared grossly pale (not shown). H and E staining of sections from 
these livers revealed that hepatocytes were filled with multilocular droplets of varying sizes (Fig. 
2A). Strikingly, these HFD-induced pathological abnormalities were completely absent in livers 
from L1-KO mice. The liver histology of HFD-fed L1-KO mice was similar to that of chow-fed 
WT mice (Fig. 2A). In addition, H and E staining revealed no signs of inflammatory leukocyte 
infiltration in livers of L1-KO mice fed an HFD and WT mice on both diets. The hepatic 
triglyceride content was 93% lower in L1-KO than WT mice on an HFD (Fig. 2B). Compared 
with chow-fed WT mice, the hepatic triglyceride content was increased by ∼14-fold in HFD-fed 
WT mice (Fig. 2B). 
NPC1L1 deficiency prevents HFD-induced insulin resistance 
Although an HFD may promote fat accumulation in the liver by simply providing more 
substrates for triglyceride synthesis, an important mechanism whereby an HFD may drive 
hepatic steatosis is by causing selective insulin resistance (26). The increased circulating insulin 
fails to suppress hepatic gluconeogenesis but can promote hepatic lipogenesis (25). To establish 
the relationship between hepatic steatosis and plasma insulin levels in our animal models, plasma 
insulin and glucose concentrations were measured under different diet conditions. As expected, 
12 weeks of HFD feeding in WT mice significantly increased the plasma insulin level under both 
fed and fasted states and this increase was completely blunted in L1-KO mice (Fig. 3A). After 24 
weeks on an HFD, the plasma insulin level was ∼85% lower in L1-KO than WT mice after a 4 h 
fast. Despite reduced plasma insulin levels, L1-KO mice, when compared with WT mice, were 
able to maintain similar plasma glucose in fed and 4 h-fasted states and even had significantly 
lower plasma glucose concentrations after overnight fasting (Fig. 3A), suggesting an insulin 
sensitive state. Indeed, when the glucose x insulin index, an indicator of insulin sensitivity (39), 
was calculated by multiplying plasma insulin and corresponding glucose concentrations, the 
index was 67% and 81% lower in L1-KO than WT mice under fed and fasted states, respectively, 
similar to those in the chow-fed mice (Fig. 3A). To determine the glucose tolerance and systemic 
insulin sensitivity, we performed glucose and insulin tolerance tests. As expected, 16 weeks of 
HFD feeding in WT mice impaired glucose tolerance and reduced insulin sensitivity (Fig. 3B, 
C). Surprisingly, HFD-induced glucose intolerance was not improved in L1-KO mice (Fig. 3B). 
However, the systemic insulin sensitivity was increased in HFD-fed L1-KO mice relative to 
HFD-fed WT mice (Fig. 3C). The glucose intolerance seen in HFD-fed L1-KO mice may be 
attributable to reduced plasma insulin levels (Fig. 3A). To examine this possibility, plasma 
insulin levels were measured during glucose tolerance tests. Consistently, HFD-fed L1-KO mice 
had similar plasma insulin concentrations to the chow-fed mice, which were significantly lower 
than those in the HFD-fed WT mice before and after glucose challenge despite the cumulative 
increase in plasma insulin levels being similar between genotypes and between diet groups (Fig. 
3D). The fact that the significantly lower plasma insulin level in HFD-fed L1-KO mice was able 
to maintain the plasma glucose concentration to the level seen in the hyperinsulinemic HFD-fed 
WT mice further supports that L1-KO mice were more insulin sensitive. 
NPC1L1 deficiency prevents HFD-induced obesity 
Because reduced hepatic steatosis itself may contribute to improved insulin sensitivity (26), the 
cause-effect relationship between hepatic steatosis and insulin resistance in L1-KO mice remains 
to be established. Interestingly, L1-KO mice were recently shown to resist HFD-induced obesity 
(16). Improved insulin sensitivity seen in L1-KO mice may result partly from a reduction in 
HFD-induced weight gain. In this long-term HFD study, we monitored weight gain and food 
intake in our mice. Compared with a chow diet, HFD feeding dramatically promoted body 
weight gain and a 2-fold increase in epididymal fat pad weight in WT mice (Table 1). Although 
L1-KO and WT mice gained weight continuously during the diet period, after 24 weeks on an 
HFD, L1-KO mice weighed ∼35.5% less than WT mice, which was associated with a 70% 
reduction in epididymal fat pad weight (Table 1). No differences were observed for plasma 
triglyceride, nonesterified fatty acids, adiponectin, and the ketone body β-hydroxybutyrate 
between L1-KO and WT mice on an HFD (Table 1). 
The reduced weight gain in L1-KO mice could not be explained by a reduction in food intake 
because both L1-KO and WT mice consumed the same amount of food daily (Table 1). A 
previous study showed that L1-KO mice on an HFD have a moderate but significant reduction in 
intestinal fat absorption as assessed by a very sensitive and accurate method (16). Using the same 
method (29), we found that the intestinal total fatty acid absorption was reduced by 7.8% (Fig. 
4A) with greater reductions observed for fatty acids C18:0 and 16:0 that were decreased by 
12.9% and 8.7% (Fig. 4B), respectively, in L1-KO versus WT mice. 
Hepatic de novo fatty acid synthesis is significantly reduced in L1-KO relative to 
WT mice on an HFD 
To gain more insight into the protective mechanisms of NPC1L1 deficiency on hepatic steatosis 
in L1-KO mice, we examined hepatic levels of mRNAs for genes involved in lipogenesis, fatty 
acid oxidation, glucose metabolism, and LXR activation by qPCR. As seen in supplementary 
Table II, hepatic mRNA levels of all the lipogenic genes examined were lower in L1-KO than 
WT mice including malic enzyme, acetyl CoA carboxylase 1, fatty acid synthase, stearoyl CoA 
desaturase-1, and glycerol 3-phosphate acyltransferase 1. Glucokinase is an enzyme that 
activates glucose to form glucose-6-phosphate, a common substrate for both fatty acid synthesis 
and glycolysis, thus playing a critical role in hepatic lipogenesis and blood glucose homeostasis. 
Intriguingly, the hepatic mRNA level for this rate-limiting enzyme in converting glucose to fat 
was substantially reduced in L1-KO versus WT livers, which may reflect its positive regulation 
by insulin (40, 41). Because we measured mRNA levels by using pooled samples, we measured 
hepatic levels of mRNAs for SREBP-1c, acetyl CoA carboxylase 1, and glucokinase in 
individual samples in each group. They were significantly reduced (Fig. 5A), in line with data 
from pooled samples. Furthermore, we measured de novo hepatic fatty acid synthesis and it was 
significantly decreased by 63% in L1-KO compared with WT mice on an HFD (Fig. 5B). 
Carbohydrate responsive element-binding protein (ChREBP) is a glucose sensor (42). Hepatic 
levels of mRNAs for this gene and genes in gluconeogenesis such as phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase were similar between L1-KO and WT mice 
(supplementary Table II). 
To determine if NPC1L1 deficiency reduced hepatic steatosis by increasing fatty acid oxidation, 
we examined hepatic levels of mRNAs for peroxisome proliferator-activated receptor α, 
peroxisome proliferator-activated receptor γ coactivator-1α and peroxisome proliferator-
activated receptor γ coactivator-1β, acyl-CoA oxidase, and carnitine palmitoyltransferase-1 
(supplementary Table II). Although hepatic mRNA levels of acyl-CoA oxidase and carnitine 
palmitoyltransferase-1 were lower in L1-KO mice relative to WT mice, hepatic fatty acid 
oxidation activity was similar between the two genotypes (Fig. 5C). 
To examine if NPC1L1 deficiency reduces hepatic steatosis by increasing lipoprotein 
triglyceride secretion, we measured plasma triglyceride concentrations at various time points 
after blocking triglyceride hydrolysis with Tyloxapol. Under this condition, L1-KO and WT 
mice had similar plasma triglyceride concentrations (Fig. 5D). The hepatic triglyceride secretion 
rates were calculated and were virtually identical between the two genotypes (Fig. 5E). 
Increased hepatic triglyceride hydrolysis may attenuate fat accumulation in liver. To examine 
this possibility, we measured the hepatic triglyceride hydrolase activity in L1-KO and WT mice 
fed an HFD for 24 weeks and no differences were found (Fig. 5F). 
NPC1L1 deficiency reduces hepatic oxidative stress 
Protection against lipid accumulation may prevent lipid peroxidation in liver. To examine this 
possibility, we measured hepatic malondialdehyde, a product of lipid peroxidation, as TBARS. 
After 24 weeks of HFD feeding, the hepatic content of malondialdehyde was significantly 
reduced by ∼29% in L1-KO versus WT mice (Fig. 6A). To assess the oxidative state of livers, 
we measured hepatic GSH/GSSG ratio in our mice. The GSH/GSSG ratio was slightly but 
significantly increased in L1-KO livers relative to WT livers (Fig. 6B). 
DISCUSSION 
This study was the first to systemically and mechanistically examine how genetic inactivation of 
NPC1L1 in mice prevents HFD-induced fatty liver. In this study, we not only showed that 
NPC1L1 deficiency prevents HFD-induced hepatic steatosis, weight gain, and insulin resistance, 
but also demonstrated that these phenotypic alterations are associated with reduced circulating 
insulin levels, hepatic de novo fatty acid synthesis, and hepatic levels of mRNAs for lipogenic 
genes including glucokinase, an enzyme critical in conversion of glucose to fat. Given that 
elevated blood insulin increases hepatic lipogenic gene expression via transcription factors such 
as SREBP-1c (23, 42), and glucokinase is an important mediator in this lipogenic pathway (43), 
our data demonstrated for the first time that NPC1L1 deficiency in mice protects against HFD-
induced hepatic steatosis by reducing hepatic lipogenesis at least in part through preventing 
HFD-induced insulin resistance and the associated hyperinsulinemia. Our findings, together with 
early reports showing that ezetimibe improves hepatic steatosis in rodents (12–15) and rabbits 
(44), warrant further studies of ezetimibe and NPC1L1 effects on fatty liver diseases and 
associated metabolic disorders. 
Increased insulin sensitivity in L1-KO mice was supported by significantly lower plasma insulin 
levels in both fed and fasted states (Fig. 3A), systemic insulin sensitivity measured by insulin 
tolerance test (Fig. 3C), and lower insulin levels during the glucose stimulation (Fig. 3D). During 
the glucose tolerance test, L1-KO mice were glucose intolerant (Fig. 3B), which may be related 
to the substantially lower plasma insulin levels in these animals. The lower index of insulin 
sensitivity (glucose × insulin) (Fig. 3A) further supports improved insulin sensitivity in L1-KO 
mice because it indicates that these animals require less insulin to maintain the plasma glucose to 
the level seen in WT mice whose plasma insulin is much higher compared with L1-KO mice. It 
is currently unclear how NPC1L1 deficiency prevents HFD-induced insulin resistance and 
hyperinsulinemia. The major defect in L1-KO mice is the blockade of intestinal cholesterol 
absorption, which results in cholesterol deficit in the body. Interestingly, depletion of cell 
membrane cholesterol content has been shown to improve insulin sensitivity in cultured 
adipocytes (45, 46). Statins, which lower blood cholesterol by inhibiting HMG-CoA reductase 
activity, have been reported to improve insulin sensitivity in human subjects with metabolic 
syndrome (47, 48). It is possible that NPC1L1 deficiency prevents HFD-induced insulin 
resistance by reducing whole-body cholesterol pool. Alternatively, the reduced weight gain may 
partly explain the insulin sensitive phenotype in L1-KO mice. 
It has yet to be molecularly elucidated how genetic inactivation of NPC1L1 in mice prevents 
HFD-induced obesity. The daily food intake was similar between WT and L1-KO mice (Table 1) 
and the total intestinal fat absorption was reduced only by 7.8% in L1-KO mice (Fig. 4A), 
suggesting that the reduced energy intake is an unlikely explanation and L1-KO mice may have 
increased energy expenditure or thermogenesis. Intriguingly, we found that increasing the 
amount of cholesterol in an HFD to a level similar to that in a typical Western diet suffices to 
rescue HFD-induced weight gain in L1-KO mice (49), indicating the involvement of cholesterol-
dependent mechanisms. Dietary cholesterol has been implicated in the regulating of diet-induced 
obesity in LXR deficient mice through unknown mechanisms (50), though the effect appears to 
be opposite to what we have seen in L1-KO mice. Nevertheless, further studies are warranted to 
molecularly define how dietary cholesterol regulates fat storage. 
In the absence of dietary cholesterol such as in our HFD, NPC1L1 mainly mediates reabsorption 
of bile-derived cholesterol, thereby preventing excessive loss of endogenous cholesterol. L1-KO 
relative to WT mice on an HFD have reduced hepatic and plasma cholesterol due to reduced 
intestinal reabsorption and increased fecal excretion of endogenously derived cholesterol (Fig. 
1). Excessive amounts of cholesterol are lipogenic through activation of LXR by its metabolites 
(20, 51). In this study, the hepatic levels of mRNAs for two LXR target genes, ATP-binding 
cassette transporter G5 and phospholipid transfer protein, were lower in L1-KO than WT mice. 
In a previous study, we also showed that T0901317, a synthetic LXR agonist, does not 
significantly increase hepatic triglyceride in L1-KO mice as it does in WT mice (22). Thus, 
NPC1L1 deficiency may have prevented HFD-induced hepatic steatosis in part by reducing 
cholesterol-dependent LXR activation in liver (Fig. 7). 
Intestinal fat absorption was reduced by 7.8% in L1-KO mice (Fig. 4A). Although this small 
reduction in fat absorption cannot explain the more than 90% reduction in hepatic triglyceride, it 
may account for a small proportion of the decrease in overnutrition-induced hepatic steatosis 
over long periods. An important question is, how does a cholesterol transporter modulate fat 
absorption? A potential mechanism may be that inhibition of intestinal cholesterol absorption 
somehow alters intestinal expression of genes involved in fatty acid uptake and transport. 
Consistent with this, fatty acid transport protein (FATP) 4 was reported to be reduced in the 
small intestine of L1-KO mice on an HFD (16). We also found that mRNAs for FATP4 and 
another fatty acid transporter Cluster Determinant (CD) 36 were substantially reduced in the 
jejunum of L1-KO versus WT mice (supplementary Table I). 
Elevated plasma glucose not only stimulates insulin secretion from pancreatic β-cells, but also 
activates ChREBP, a transcription factor that promotes hepatic glycolysis and lipogenesis (42). 
In this study, blood glucose levels were comparable between L1-KO and WT mice in the fed 
state and during glucose challenge (Fig. 3A, B). However, in the overnight-fasted L1-KO mice, 
plasma glucose is lower (Fig. 3A) and additionally, the reduction in glucokinase mRNA suggests 
that conversion of glucose to fat may be decreased, which may also partly contribute to the 
steatoprotective role of NPC1L1 deficiency. 
Another factor known to promote hepatic steatosis is the increased flux of free fatty acids into 
the liver as a result of increased fat lipolysis. Donnelly et al. (52) reported that in subjects with 
NAFLD, the plasma free fatty acid pool accounted for ∼60% of triglyceride content in liver. 
Under normal physiological states, free fatty acids are stored in adipose tissue as triglyceride but 
in the insulin resistant adipose tissue, insulin fails to fully suppress fat lipolysis, resulting in 
increased release of free fatty acids into blood. However, the plasma concentrations of 
nonesterified fatty acids were similar between L1-KO and WT mice on an HFD (Table 1), 
arguing against an important role of fat lipolysis in modulating hepatic steatosis in our model. 
Increases in fatty acid oxidation, triglyceride hydrolysis, and triglyceride secretion via 
lipoproteins in liver may prevent hepatic steatosis but we found that the hepatic fatty acid 
oxidation activity, triglyceride hydrolase activity, and triglyceride secretion rates are similar 
between L1-KO and WT mice (Fig. 5). In addition, plasma concentrations of β-hydroxybutyrate 
and triglyceride are comparable between the two genotypes (Table 1). Collectively, these 
findings demonstrate that the aforementioned factors were unlikely to have played an important 
role in protecting L1-KO mice from hepatic steatosis. 
It was recently reported that leptin receptor deficient Zucker rats treated with ezetimibe have 
reduced hepatic reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, and 
mitochondrial cholesterol, and based on these observations, the authors hypothesized that liver 
NPC1L1 contributes to hepatic insulin resistance through free cholesterol accumulation and 
subsequent ROS generation and ER stress (13). Although this hypothesis is attractive and we 
also observed a reduction in hepatic oxidative stress in L1-KO relative to WT mice (Fig. 6), two 
important points should be made: 1) NPC1L1 protein is undetectable in rodent livers and the 
effect could be a result of NPC1L1 inhibition by ezetimibe in intestine rather than liver; and 2) 
although ROS generation and ER stress can cause hepatic steatosis, hepatic steatosis can also 
cause these cellular disorders, making it difficult to establish a cause-effect relationship. 
Figure 7 summarizes the potential roles of NPC1L1 deficiency or ezetimibe treatment in 
protecting liver from steatosis induced by an HFD and cholesterol. Our data suggest that genetic 
deletion of NPC1L1 in mice may protect against HFD-induced hepatic steatosis mainly by 
preventing HFD-induced insulin resistance and hyperinsulinemia. Suppression of other lipogenic 
factors such as cholesterol-dependent LXR activation and glucose-dependent ChREBP activation 
may have contributed in part to the beneficial effects of NPC1L1 deficiency on fatty liver 
development. Further studies are required to define how NPC1L1, a cholesterol transporter that 
mainly mediates intestinal cholesterol absorption in rodents, modulates HFD-induced insulin 
resistance and obesity. 
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Figures and Tables 
Fig. 1. 
 
L1-KO mice on an HFD have (A) reduced intestinal cholesterol absorption, (B) increased fecal 
neutral sterol excretion, (C) elevated endogenous hepatic cholesterol synthesis, and decreased 
plasma (D) and hepatic (E) cholesterol. The amount of cholesteryl ester (CE) was calculated by 
subtracting free cholesterol (FC) from total cholesterol (TC) and multiplying by 1.67 to convert 
to cholesteryl ester mass. *P < 0.05, **P < 0.001, L1-KO relative to wild-type (WT) mice on a 
high-fat diet (HFD); #P < 0.05, ##P < 0.001, WT mice on chow diet compared with WT mice on 
an HFD (n = 5–7). 
 
TABLE 1. 
L1-KO mice are resistant to HFD-induced obesity 
 WT (Chow) WT (HFD) L1-KO (HFD) 
BW (g) 30.0 ± 1.6# 41.1 ± 2.3 26.5 ± 0.7** 
WAT weight (g) 0.99 ± 0.24# 3.05 ± 0.32 0.90 ± 0.07** 
WAT/BW ratio 0.02 ± 0.008## 0.07 ± 0.005 0.03 ± 0.002** 
Liver weight (g) 1.15 ± 0.05## 2.32 ± 0.26 0.99 ± 0.05* 
Liver/BW ratio 0.04 ± 0.001## 0.06 ± 0.004 0.04 ± 0.001* 
Food Intake (g/day) N.D. 2.2 ± 0.1 2.3 ± 0.1 
Plasma triglyceride (mg/dl) 71.2 ± 7.28# 36.7 ± 6.53 26.8 ± 5.45 
Plasma NEFA (mmol/L) N.D. 0.89 ± 0.06 0.73 ± 0.06 
Plasma adiponectin (μg/ml) N.D. 7.03 ± 0.42 5.88 ± 0.41 
Plasma β-hydroxybutyrate (mmol/L) N.D. 0.32 ± 0.04 0.39 ± 0.07 
Food intake was measured in mice on an HFD for 20 weeks. Body weight (BW), tissue and 
plasma parameters were determined in mice on chow or an HFD for 24 weeks. Each value 
represents the mean ± SEM of 6–8 values. *P < 0.05, **P < 0.001 (L1-KO relative to WT mice 
on HFD); #P < 0.05, ##P < 0.001 (WT mice on chow relative to WT mice on an HFD). WAT, 
white adipose tissue; NEFA, nonesterified fatty acid; N.D., not determined. 
 
Fig. 2. 
 
L1-KO mice are resistant to HFD-induced hepatic steatosis. Livers were collected from WT male 
mice on both chow and an HFD and L1-KO male mice fed an HFD for 24 weeks. A: 
Representative H and E staining of liver sections. B: Hepatic triglyceride content (n = 6–7), **P 
< 0.001, L1-KO relative to WT mice on an HFD; ##P < 0.001, WT mice on chow diet compared 
with WT mice on an HFD. 
 
Fig. 3. 
 
L1-KO relative to WT mice on an HFD are more insulin sensitive. A: Plasma levels of insulin 
and glucose, and the index of insulin sensitivity (insulin x glucose) in fed and overnight (O/N) 
fasted mice on an HFD or chow diet for 12 weeks and in 4 h fasted (during daylight cycle) mice 
on an HFD or chow diet for 24 weeks (n = 5–6). B: Glucose tolerance test in mice fed an HFD or 
chow diet for 16 weeks (n = 5–7). C: Insulin tolerance test in mice fed an HFD or chow diet for 
15 weeks (n = 5). D: Glucose-stimulated insulin secretion in mice fed an HFD or chow diet for 5 
weeks (n = 5–6). The area under the curve for glucose tolerance test and insulin tolerance test, 
and the incremental area under the curve for glucose-stimulated insulin secretion were calculated 
and shown in the right panel of each respective figure. AU, arbitrary unit. *P < 0.05, **P < 0.01, 
L1-KO versus WT mice on an HFD for the same treatment or at the same time point. #P < 0.05, 
##P < 0.01, WT mice on chow versus an HFD for the same treatment or at the same time point. 
 
  
Fig. 4. 
 
L1-KO mice on an HFD have reduced intestinal absorption of total fatty acids (A) and specific 
fatty acid species (B). *P < 0.05; **P < 0.001 (n = 6). 
Fig. 5. 
 
L1-KO relative to WT mice show reduced hepatic fatty acid synthesis. A: Hepatic mRNA levels 
of genes involved in endogenous lipogenesis and an LXR target phospholipid transport protein 
(PLTP). Hepatic mRNA levels were measured by qPCR with individual total RNA samples from 
each group (n = 3). Cyclophilin was used as an internal control. Hepatic fatty acid synthesis (B) 
and fatty acid oxidation (C) in 4 h fasted mice on an HFD for 6 weeks (n = 6). D: Plasma 
triglyceride levels before and after Tyloxapol injection. E: Hepatic triglyceride secretion rates in 
mice on an HFD for 4 weeks (n = 5). F: Hepatic triglyceride hydrolase activity in mice on an 
HFD for 24 weeks (n = 6). *P < 0.05; **P < 0.001. ACC1, acetyl CoA carboxylase 1; GK, 
glucokinase. 
  
Fig. 6. 
 
L1-KO mice display reduced hepatic oxidative stress. A: Hepatic content of malondialdehyde 
(MDA) as TBARS (n = 6). B: Hepatic GSH/GSSG ratio (n = 4). *P < 0.05. 
Fig. 7. 
 
Outline of known pathways involved in hepatic steatosis induced by an HFD and cholesterol, 
and potential roles of NPC1L1 deficiency or ezetimibe treatment in modulating these pathways. 
An HFD causes insulin resistance, a state that is associated with hyperinsulinemia and 
hyperglycemia. Elevated blood insulin and glucose activate transcription factors SREBP-1c and 
ChREBP, respectively, to increase hepatic lipogenic gene expression. Glucokinase (GK) plays a 
critical role in these lipogenic pathways. Intestinal cholesterol absorption promotes hepatic 
lipogenesis via cholesterol-dependent activation of LXR. NPC1L1 deficiency or ezetimibe 
treatment can block: 1) HFD-induced insulin resistance in part by reducing intestinal fat 
absorption and weight gain, and 2) cholesterol-driven lipogenesis by inhibiting intestinal 
cholesterol absorption, which together may substantially suppress hepatic triglyceride (TG) 
synthesis, thereby preventing dietary fat-induced hepatic steatosis. 
 
Supplemental TABLE S1. Relative amounts of mRNAs in livers and jejuna from L1-KO mice 
as compared with values in WT mice 
                                                         Relative amount 
                                                            in L1-KO mice 
Hepatic cholesterol biosynthesis 
   SREBP-2                                                       0.81 
   HMG-CoA Reductase                                   1.43 
   HMG-CoA synthase                                      1.85 
   Squalene synthase                                        1.3 
Intestinal lipid metabolism 
   HMG-CoA synthase                                      1.23 
   ABCA1                                                           0.23 
   Fatty acid transport protein 4                         0.62 
   Cluster Determinant (CD) 36                         0.29 
 
Mice were fed HFD for 24 weeks. Total RNAs were extracted from each liver tissue or 
jejunal tissue (the second proximal segment of 5 equal segments of the whole small intestine). 
The equal amount of total RNAs from each tissue in each group (n = 6) was pooled and 
subjected to qPCR as described under Methods. Cyclophilin was used as the internal control. 
Values represent the amount of mRNA relative to that in WT mice, which is arbitrarily defined 
as 1. ABCA1, ATP-binding cassette transporter A1 
  
 
 
Supplemental TABLE S2. Relative amounts of mRNAs in livers from L1-KO mice as 
compared with values in WT mice 
                                                         Relative amount 
                                                            in L1-KO mice 
Lipogenesis 
   Acetyl CoA carboxylase                                 0.54 
   Fatty acid synthase                                        0.34 
   Malic enzyme                                                 0.58 
   Stearoyl-CoA desaturase-1                            0.4 
   Glycerol-3-phosphate acyltransferase 1        0.48 
   Glucokinase                                                   0.32 
Glucose metabolism 
   ChREBP                                                        0.83 
   Glucose-6-phosphatase                                 0.7 
   Phosphoenolpyruvate carboxykinase            0.94 
Fatty acid oxidation 
   PPAR                                                           0.72 
   PGC-1                                                          0.88 
   PGC-1β                                                          1.28 
   Acyl-CoA oxidase                                           0.45 
   Carnitine palmitoyltransferase-1                  0.43 
LXR target genes 
   ABCG5                                                           0.52 
   Phospholipid transfer protein                         0.66 
 
Mice were fed HFD for 24 weeks. Total RNAs were extracted from each liver tissue 
and the equal amount of total RNAs from each sample in each group (n = 6) was pooled and 
subjected to qPCR as described under Methods. Cyclophilin was used as the invariant 
control. Values represent the amount of mRNA relative to that in WT mice, which is arbitrarily 
defined as 1. ABCG5, ATP-binding cassette transporter G5; PPAR, peroxisome proliferator-
activated receptor; PGC, PPAR gamma coactivator 
 
